Compare Stocks: REGN vs. MRNA vs. RVMD vs. ALNY
Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
REGNMRNARVMDALNY
Market Snapshot
Current market context for the selected companies.
REGN
$842.96
Market Cap
$87.72B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-09-03
MRNA
$148.93
Market Cap
$60.21B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-09-03
RVMD
$210.83
Market Cap
$44.85B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-09-03
ALNY
$264.07
Market Cap
$35.78B
Sector
Healthcare
Industry
Biotechnology
Data through
2026-09-03
Performance
Absolute returns and relative performance versus SPY.
| Metric | REGN | MRNA | RVMD | ALNY |
|---|---|---|---|---|
| 1 Month | +9.7% | +164.7% | +6.9% | +15.5% |
| 1 Month vs SPY | +9.3% | +164.4% | +6.5% | +15.1% |
| 3 Months | +34.1% | +188.7% | +35.4% | -13.0% |
| 3 Months vs SPY | +32.0% | +186.6% | +33.3% | -15.1% |
| 6 Months | +10.2% | +176.7% | +111.6% | -17.6% |
| 6 Months vs SPY | -3.2% | +163.2% | +98.2% | -31.0% |
| 1 Year | +49.5% | +519.3% | +430.1% | -41.0% |
| 1 Year vs SPY | +29.5% | +499.2% | +410.1% | -61.0% |
| 2 Years | -28.5% | +91.9% | +404.4% | -8.0% |
| 2 Years vs SPY | -66.9% | +53.5% | +366.0% | -46.4% |
Growth & Profitability
Operating growth, margins and capital efficiency.
Valuation
Common valuation multiples shown side by side.
Cash Flow & Balance Sheet
Cash generation and leverage context.
Earnings Outlook
Upcoming earnings expectations when available.